Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 6, 2006, Pages 571-576

  Delea, Thomas E ^a   McKiernan, James ^c   Brandman, Jane ^b   Edelsberg, John ^a   Sung, Jennifer ^b   Raut, Monika ^c   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NONE

Author keywords

Bone metastases; Complications; Costs; Lung cancer; Observational study

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERCALCEMIA; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SPINAL CORD COMPRESSION; BONE TUMOR; CANCER INVASION; CASE CONTROL STUDY; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; ECONOMICS; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROBABILITY; REFERENCE VALUE; RISK ASSESSMENT;

AGED; BONE NEOPLASMS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 34247890126     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200607000-00012     Document Type: Article

References (21)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-1594.
2. Weinfurt KP, Li Y, Castel LD, et al. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer (abstract). Ann Oncol 2002;13(Suppl 5):180.
3. Weinfurt KP, Castel LD, Li Y, et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-175.
4. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007.
5. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
6. Saad F, Gleason DM, and Murray R for the Zoledronic Acid Prostate Cancer Study Group. A randomized controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
7. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17:846-854.
8. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-3157.
9. Canil CM, Tannock IF. Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone? J Natl Cancer Inst 2002;94:1422-1423.
10. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-79.
11. Groot MT, Boeken Kruger CGG, Pelger RCM, et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-232.
12. Delea T, Mckiernan J, Liss M, et al. Cost of skeletal complications in patients with bone metastases of lung cancer (abstract). Lung Cancer 2003;41(Suppl 2):S57.
13. Rubin DB. Estimating causal effects from large datasets using propensity scores. Ann Intern Med 1997;127:757-763.
14. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
15. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Resp Crit Care Med 2003;168:49-53.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with IDC-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
17. Center for Medicare and Medicaid Services. The Hospital Cost Report Information System (HCRIS). Baltimore, MD, 1996. Available at: http://cms.hhs.gov/data/download/default.asp. Accessed March 23, 2006.
18. U.S. Department of Labor, Bureau of Labor Statistics. Consumer price indices. Available at: http://www.bls.gov/cpi/home.htm. Accessed March 23, 2006.
19. Lin DY, Fewere EJ, Etzioni R, et al. Estimating costs from incomplete follow-up data. Biometrics 1997;53:113-128.
20. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;18:103(Suppl 2A): 12S-17S.
21. Guralnik JM, Alecxih L, Branch LG, et al. Medical and long-term care costs when older persons become more dependent. Am J Public Health 2002;92:1244-1245.